Thompson Rahsaan
Known title: Chief Legal & ComplianceCIK: 0001788524
Associated companies
Transaction History
| ZVRA | ▼ Sell | Open Market | 42,666 | $475K | 8/14/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 34,557 | $438K | 6/22/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 66,667 | — | 6/21/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 1,794 | $20K | 5/11/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 11,333 | — | 1/30/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 4,080 | $36K | 1/30/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 24,000 | $221K | 6/26/2025 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 66,666 | — | 6/21/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.